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Abstract. Matrix metalloproteinases (MMPs) have been well 
characterized for their ability to degrade extracellular matrix 
proteins and, thus, they have been studied to elucidate their 
involvement in both tumor development and progression. In the 
present study, attention was focused on MMP-15 and MMP-19, 
two less known members of the MMP family. The expression 
profile of MMP-15 and -19 was assayed in samples of normal 
colorectal mucosa, microadenomas and cancer using confocal 
analysis, western blotting and quantitative reverse transcription 
polymerase chain reaction (qRT-PCR). Both qRT-PCR and 
western blotting showed that MMP-15 and MMP-19 appeared 
to be upregulated during colorectal tumorigenesis, with different 
expression patterns: MMP-15 expression level increases from 
normal mucosa to microadenomas, with a reduced level in 
cancer with respect to microadenomas; the semiquantitative 
immunofluorescence analysis showed a stromal localization of 
this protein in the early phases of neoplastic transformation. 
Increasing amount of MMP-19 mRNA and protein levels were 
observed in the progression of colonic lesions; MMP-19 staining 
increased in the normal mucosa-microadenoma-carcinoma 
sequence. Such different expression patterns, are probably due 
to the different roles played in colorectal tumorigenesis by these 
two molecules. Conflicting data on the role of these proteins in 
tumor progression have been reported, thus, an improved under-
standing of the biological roles of MMPs, in particular the lesser 
known members such as MMP-15 and 19, in colorectal cancer 
may lead to a re-evaluation of the use of MMP inhibitors and 
suggests the need of integrated translational studies on MMP 
expression patterns.
Introduction
Matrix metalloproteinases (MMPs) play a sophisticated role 
in cancer development due to their abilities to degrade various 
substrates. MMPs are generally classified as pro-angiogenic 
factors, since they can degrade the extracellular matrix mole-
cules to facilitate tumor cell migration and invasion (1,2). This 
concept of the role of MMPs in tumor invasion and metastasis is 
currently undergoing a major reappraisal most notably as a result 
of the apparent failure of several ‘high-profile’ clinical trials of 
MMP inhibitors in cancer (3).
MMP-15 is a recently discovered membrane-type MMP 
which was originally isolated from a human lung cDNA 
library, and it consists of a 76-kDa product with 73.9% overall 
similarity to MMP-14 (4,5). Despite the high degree of struc-
tural similarity of these two MMPs, differences in substrate 
specificity (6,7), as well as tissue or cellular localization, have 
been demonstrated (8). Although MMP-15 is reported to play 
a similar role to MMP-14 in cell invasion (9), its implication 
remains to be elucidated; the importance and role of MMP-14 
in promoting tumor growth have been extensively investigated 
(10), in contrast to the role and function of MMP-15 which is 
just beginning to be addressed. It has been reported involved 
in the progression of various kinds of cancers, such as breast, 
cervical, and ovarian cancer (11-13). Recent reports indicate 
MMP-15 as an anti-apoptotic factor in cancer cells (14). 
Moreover, MMP-15 is also identified as prognostic predictor 
for disease-free survival in colorectal cancer (15).
Matrix metalloproteinase 19 (MMP-19) is a secreted 
protease, able to cleave various extracellular matrix (ECM) 
components and it is up-regulated under inflammatory condi-
tions. MMP-19 was first isolated as an autoantigen, from the 
synovium of rheumatoid arthritis patients (16). The role of 
MMP-19 in promoting tumor invasion is as controversial as 
for all other MMPs. MMP-19 is up-regulated in astroglial 
tumor and melanoma (17,18), and it is reported to increase 
human keratinocyte cell proliferation, migration and adhesion 
on type I collagen through the IGF-signalling pathway (19). 
These findings suggest that MMP-19 may play a role during 
malignant transformation. On the other hand, some studies 
reported that MMP-19 is down-regulated or even lost during 
neoplastic progression in breast and skin (20-22). Evidence is 
emerging for important biological roles of MMPs including 
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apoptosis, cell proliferation and cell differentiation (14). Much 
of the evidence linking MMPs to wider biological roles in 
both tumor development and progression are being provided 
by the study of colorectal cancer, since it represents a well-
defined and extensively studied model of tumorigenesis as 
well as being among the most common malignancies world-
wide and one of the leading causes of cancer-related death. 
In this respect, the present study focused on the analysis of 
the expression of MMPs 15 and 19, from the earliest stages of 
neoplastic transformation to cancer. The results clearly show 
that the proteins investigated exhibit different behavior during 
tumor progression.
Materials and methods
Study population. Samples (n=56) of normal colorectal mucosa 
(NM) were collected from 14 patients during colonoscopy, at 
least 3 samples for each patient. One sample for each patient was 
fixed in formalin and embedded in paraffin for histology and 
RNA extraction; the others were frozen at -80˚C. All patients 
had normal colonoscopy. Thirty microadenomas (MA) were 
also identified in 16 patients, and removed after operation for 
colorectal cancer on surgical specimens, after staining of the 
mucosa with a 0.1% methylene-blue solution in saline, and obser-
vation under a dissecting microscope (23). All microadenomas 
were defined as dysplastic aberrant crypt foci at histology and, 
indeed, they could be referred to as microadenomas. Ten MA 
were fixed in formalin and embedded in paraffin, the others 
were frozen at -80˚C. Finally, 33 samples of colorectal cancer 
(CRC) were collected from 11 patients operated on for cancer, 
fixed in formalin or frozen at -80˚C, as described above.
All the patients enrolled in this study, who underwent 
colonoscopy or surgical resection for colorectal cancer at the 
University Hospital of Modena, gave their informed written 
consent to the study protocol, which was approved by the local 
Ethics Committee.
Immunofluorescence confocal microscopy. Immunofluorescence 
analysis was carried out to evaluate the expression of MMP-15 
and MMP-19 proteins. Multiple labelling of the samples was 
carried out to analyze the co-localization of MMP-15/MMP-19 
with vimentin, myeloperoxidase, CD3 and CD20, in order to 
determine their possible interaction. Samples of NM, MA, and 
CRC were fixed in 4% paraformaldehyde in PBS, cryoprotected 
in 15% sucrose in PBS, and frozen in isopentane cooled in 
liquid nitrogen. Horizontal cryosections of the samples were 
cut (10-µm thick), and hematoxylin and eosin staining was 
performed on sections to control tissue integrity. After a treat-
ment with 3% BSA in PBS for 30 min at room temperature, the 
cryostatic sections were incubated with the primary antibodies 
(rabbit anti-MMP-15, rabbit anti-MMP-19, Novus Biologicals; 
mouse anti-vimentin, mouse anti-myeloperoxidase, mouse 
anti-CD3, mouse anti-CD20 DakoCytomation); diluted 1:25 
in PBS containing 3% BSA for 1 h at room temperature. After 
washing in PBS, the samples were incubated for 1 h at room 
temperature with the secondary antibodies diluted 1:20 in PBS 
containing 3% BSA (sheep anti-mouse FITC conjugated, goat 
anti-rabbit Cy3 conjugated, goat anti-rabbit TRITC-conjugated; 
Sigma). After washing in PBS and in H2O, the samples were 
counterstained with 1 µg/ml DAPI in H2O and then mounted 
with anti-fading medium (0.21 M DABCO and 90% glycerol in 
0.02 M Tris, pH 8.0). Negative control samples were not incubated 
with the primary antibody. The confocal imaging was performed 
on a Leica TCS SP2 AOBS confocal laser scanning microscope. 
For DAPI and Cy3 double detection, samples were sequentially 
excited with the 405-nm/25-mW line of a blue diode laser and 
the 543-nm/1.2-mW line of a HeNe laser. The emission signals 
from DAPI and Cy3 were detected by two photomultiplier tubes. 
The samples, processed for triple fluorescence (DAPI, FITC and 
Cy3), were sequentially excited with the 405-nm/25-mW lines of 
a blue diode laser, the 488-nm/20-mW lines of the Argon laser 
and the 543-nm/1.2-mW lines of a HeNe laser.
Excitation and detection of the samples were carried out in 
sequential mode to avoid overlapping of signals. Sections were 
scanned with laser intensity, confocal aperture, gain and black-
level setting kept constant for all samples. Optical sections were 
obtained at increments of 0.3 µm in the z-axis and were digitized 
with a scanning mode format of 512x512 or 1024x1024 pixels and 
256 grey levels. The confocal serial sections were processed with 
the Leica LCS software to obtain three-dimensional projections. 
Image rendering was performed by adobe Photoshop software.
Evaluation of MMP-15 and MMP-19 immunofluorescence. 
The evaluation was carried out in a subset of samples, 6 for 
NM, 6 for MA, and 6 for CRC, randomly selected. The original 
green fluorescent confocal images were converted to grey-
scale and median filtering was performed. An intensity value 
ranging from 0 (black) to 255 (white) was assigned to each 
pixel. Background fluorescence was subtracted and the immu-
nofluorescence intensity (IF) was calculated as the average for 
each selected area.
To quantify MMP-15 and -19 expression, all blocks were 
sectioned exhaustively and 3-4 slides were examined at magni-
fication x40 for each patient. In each section almost 60 crypts 
were present. Starting randomly, 3 fields of vision for each 
section were used for sampling all crypts within the unbiased 
sampling frame.
The fluorescence intensity at the selected areas, linearly 
correlated with the number of pixels, was quantitatively analysed 
using the standard imaging analysis software of the NIS-Elements 
system. To each sample was assigned a code number and the 
score, referred to as immunofluorescence intensity score (IFIS), 
determined by an observer who was blind to tissue groups during 
analysis (23).
For each patient, 3-4 slides were examined at magnification 
x40 in order to identify the type/amount of stromal cells in 
which the co-localization of each MMP (15 or 19) was present. 
The correspondence between co-localization and cellular 
type was the following: MMP-15/19 with vimentin, identifies 
fibroblast-like cells; MMP-15/19 with myeloperoxidase, iden-
tifies neutrophils and macrophages; MMP-15/19 with CD3 
identifies T- lymphocytes; MMP-15/19 with CD20 identifies 
B-lymphocytes. With respect to a total amount of 200 MMP- 
positive stromal cells identifiable in each slide, the number of 
cells presenting merge signal was recorded.
This type of histomorphometrical evaluation (cell number, 
200) is the best solution to obtain a sampling independent from 
the dimensions of the histological section. To each sample was 
assigned a code number and the score was determined by an 
observer who was blind to tissue groups during analysis.
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Western blot analysis. Whole cell lysates were obtained from the 
samples of NM, MA, and CRC, extracted with hypotonic buffer 
(50 mM Tris-Cl, pH 7.8, containing 1% Nonidet P40, 140 mM 
NaCl, 0.1% SDS, 0.1% Na deoxycholate, 1 mM Na3VO4, and 
freshly added protease inhibitor cocktail). Lysates were then 
cleared by centrifugation for 15 min in a refrigerated centrifuge, 
at maximal speed, and immediately boiled in SDS sample buffer. 
Protein extract (40 µg) from each sample (NM, MA, and CRC) 
was electrophoresed on SDS-PAGE and transferred to nitrocel-
lulose membranes. The protocols of the Western blotting were 
performed as previously described (23). The membranes were 
blocked with 3% dry milk and 2% BSA in PBS-T and was incu-
bated with the following antibodies, diluted 1:1000 overnight at 
4˚C under agitation: rabbit anti-MMP-15, rabbit anti-MMP-19, 
Novus Biologicals. After washing, the membranes were incubated 
with secondary HPR-conjugated goat anti-rabbit IgG antibody 
(1:10,000) for 30 min at room temperature. Immunoreactive 
proteins were detected with ECL (Amersham). Furthermore, the 
membranes were stripped and incubated with anti-mouse α-actin 
(Sigma) to control and correct for loading error. Densitometry 
analysis was performed using a Kodak (Rochester, NY) Image 
Station 440cf system.
RNA isolation and qRT-PCR. mRNA was isolated from 
formalin-fixed, paraffin-embedded samples of all cases. Total 
RNA was extracted from 10-µm sections, using High Pure 
RNA Paraffin Kit (Roche Diagnostics S.p.A., Milan, Italy). 
RNA content was determined by spectrophotometry and first-
strand cDNA was synthesized from 2 µg of total RNA with 
Superscript VILO cDNA synthesis kit (Invitrogen S.r.l., Milan, 
Italy) according to the manufacturer's instructions.
Real-time PCR was done on the iCycler iQReal-Time 
Detection System (Bio-Rad) using Go-taq qPCR Master Mix 
(Promega, Milan, Italy) according to detailed manufacturer's 
protocols. To confirm amplification of a specific product, melting 
curve analysis was performed and PCR products were directly 
visualized on 2% low-melting agarose gels.
The MMP-15 and MMP-19 amplification results were 
normalized to the corresponding GAPDH results. Data were 
expressed as fold induction in pathological tissue compared 
to normal mucosa (∆Ct method using a reference gene or the 
Livak method) (24).
Specific primer pairs were as follows: MMP-15, forward 
5'-ccgccctcattatttatgtcc-3' and reverse 5'-attctaaacaccctgcccc-3'; 
MMP-19, forward 5'-tgctttcaagggggactatg-3' and reverse 5'-agaca 
gcagcatccaggttt-3'; GAPDH, forward 5'-agccacatcgctcagacac-3' 
and reverse 5'-gcccaatacgaccaaatcc-3' (used as normalized). The 
cycling conditions were established as follows: single cycle at 
95˚C for 2 min, 40 cycles at 95˚C for 15 sec, and at 60˚C for 
60 sec.
Statistical analysis. All quantitative data for NM, MA, and CRC 
are reported as mean ± SD or mean ± SEM. The difference in 
MMP-15 and MMP-19 average expression in the different groups 
of colorectal lesions, was tested for statistical significance using 
Kruskal-Wallis analysis, followed by Student-Newman-Keuls 
tests. p<0.05 was chosen to indicate a statistical significant 
difference.
Results
MMP-15 quantification in the early steps of colorectal carci-
nogenesis. Western blotting of cell lysates in analysing the 
Figure 1. (A) Western blotting of metalloproteinases 15 and 19 (MMP-15 and -19) in human normal colorectal mucosa (NM), microadenomas (MA), colorectal 
carcinomas (CRC). (B) Mean densitometric data of MMP-15 protein expression level. (C) Mean densitometric data of MMP-19 protein expression level (p<0.05 
for groups with the same symbol).
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protein profile of MMP-15 in normal mucosa (NM), micro-
adenomas (MA) and colorectal cancer (CRC), clearly showed 
one single weak band at the expected molecular weight 
(76 kDa) in NM, a very intense band in MA, and a less intense 
band in CRC samples (Fig. 1A).
Densitometric analysis and normalization (with equal 
amounts of protein loading) of the immunoreactivity signal from 
protein extracts of NM, MA and CRC showed that the level of 
MMP-15 protein have an upward trend from NM to MA, with 
statistical significance of the different expression. Protein levels 
slightly decreased from MA to CRC (Fig. 1B).
The qRT-PCR analysis, to investigate the MMP-15 tran-
scriptional activation, was first performed on fresh tissue, 
and then on formalin-fixed, paraffin-embedded samples, 
giving comparable yields. Fig. 2A, and Table I summarize the 
expression levels of MMP-15 in MA and CRC, versus NM. 
The amount of MMP-15 mRNA was higher in MA and in 
CRC compared to NM. Data of protein expression and mRNA 
quantification were strictly correlated: they showed a peak 
of both MMP-15 protein and mRNA in the early dysplastic 
lesions (MA), suggesting that MMP-15 activation is essential 
in the early steps of CRC development.
Stromal localization of MMP-15 in colorectal carcinogenesis. 
Confocal analysis of MMP-15 in samples of NM, MA, and 
CRC allowed to define both the distribution pattern and the 
quantification of this protein. The staining patterns of MMP-15 
varied from a diffuse mode to a granular one in the cytoplasm 
of stromal cells, appearing consistent and unchanged in the 
same samples, without considerable variation in intensity and 
localization from cell to cell.
All samples of NM were not marked at the epithelial level, 
although a few scattered areas in the adjacent stroma showed 
a moderate MMP-reactivity (Fig. 3A). In MA intense staining 
was evident in stromal cells surrounding colonic crypts, whereas 
epithelial cells did not show any expression (Fg. 3B). In CRC 
samples the overall intensity of MMP-15 staining was more 
evident in comparison with NM, although it was decreased 
compared with MA (Fig. 3C). Cancer epithelial cells showed 
undetectable MMP-15 reactivity.
These features were confirmed by the measurement of the 
MMP-15 expression levels (Table I). In order to clarify the 
role of the stromal compartment in the synthesis of MMP-15, 
we tried to identify the type of stromal cells mostly involved 
in this process. For this purpose, double immunofluorescence 
analyses were performed with the MMP-15 antibody together 
with several antibodies specific for different stromal cells, i.e., 
anti-vimentin, specific for fibroblast-like cells, anti-myeloperox-
idase, specific for neutrophils and macrophages, anti-CD3 and 
anti-CD20, which recognise T and B lymphocytes, respectively. 
Interestingly, the staining profiles observed showed the greatest 
amount of MMP-15 positive cells, ~70%, in fibroblast-like cells 
and 30% neutrophils/macrophages, as revealed by coimmu-
nostaining with MMP-15 and the antibodies specific for these 
different cell types (Fig. 3G-I). Very few MMP-15-positive 
lymphocytes were observed in the tumor stroma. This expres-
Figure 2. (A) qRT-PCR results for MMP-15 expressed as fold change with respect to NM (p<0.05 for groups with the same symbol). (B) qRT-PCR results for 
MMP-19 expressed as fold change with respect to NM (p<0.05 for groups with the same symbol).
Table I. Immunofluorescence intensity score (IFIS), and mRNA quantification of metalloproteinases 15 and 19 (MMP-15 and 
MMP-19) in human normal colorectal mucosa (NM), microadenomas (MA) and colorectal carcinomas (CRC).
 MMP-15 MMP-19 ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
 IFIS (mean ± SD) mRNA fold change IFIS (mean ± SD) mRNA fold change
  (mean ± SEM)  (mean ± SEM)
NM 30.7±9.0a 1.0    36.1±5.0a 1.0
MA 96.7±9.9a 4.9±1.3b   74.6±4.0a 3.8±0.8b
CRC 79.2±5.4a 3.8±1.2b 107.0±7.8a 4.9±2.0b
ap<0.05 between all group pairs of samples. bp<0.05 vs NM.
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sion profile was more evident in MA and CRC samples, whereas 
in NM it was difficult to identify the different cell types.
MMP-19 gradually increased from normal colorectal mucosa to 
microadenoma and carcinoma. The Western blotting profile of 
MMP-19 is shown in Fig. 1A. It was different from the MMP-15 
one. MMP-19, as the 58 kDa band, was more evident in CRC 
with respect to MA, but it was very slight in NM. The densito-
metric analysis (Fig. 1C), consistently showed that the amounts of 
MMP-19 proteins increased significantly in the progression from 
NM to CRC. Formalin-fixed paraffin-embedded samples gave 
good results also for MMP-19 mRNA. The qRT-PCR expression 
data confirmed a steady increase of MMP-19 mRNA levels from 
NM to CRC (Fig. 2B).
MMP-19 immunofluorescence in stromal and epithelial cells. 
The expression pattern of MMP-19, evaluated in the stromal 
compartments was different from that observed for MMP-15; 
Figure 3. Confocal analysis of colonic mucosa cryosections labelled by DAPI (A-F, red; I and L, blue), MMP-15 (green), MMP-19 (green); and vimentin (H, I, K 
and L, red). (A-C) The double immunolabelling performed by DAPI and MMP-15 shows an increased expression of the MMP-15 protein from normal mucosa 
(A) to microadenomas (B) which tends to decrease in carcinomas (C). (D-F) The image obtained by the merge of DAPI and MMP-19 shows a marked increase 
of staining in the sequence normal mucosa (D) -microadenoma (E) -carcinoma (F). (G-I) Samples of carcinoma stained with MMP-15, vimentin and DAPI. In 
the stromal compartment is evident the presence of many labeled cells with MMP-15 and vimentin, whose co-immunostaining (yellow) corresponds to 70% 
(arrows). (J-L) Samples of carcinoma stained with MMP-19, vimentin and DAPI. Co-localization (yellow) of MMP-19 and vimentin in stroma cells point out 
the presence of fibroblast-like cells producing MMP-19 (arrows). Scale bars, 30 (A and D), 50 (B, C, E and F), 20 (G-I) and 15 µm (J-L).
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the samples of NM showed a weak staining, whereas the protein 
expression levels tended to increase from MA to CRC (Fig. 3D-F). 
In all samples, MMP-19 positive cells filled the lamina propria 
surrounding the colonic crypts (Fig. 3F).
The semiquantitative analysis of the IFIS score of MMP-19 
showed a higher staining intensity in MA with respect to NM, 
further increased in CRC (Table I). Double immunofluorescence 
analysis aimed at identifying the type of stromal cells mainly 
involved in this process, showed a pattern similar to that observed 
for MMP-15, with a prevalence of fibroblast-like MMP-19 posi-
tive cells (Fig. 3J-L). Only a small fraction of the total population 
of myeloperoxidase positive cells showed a coimmunostaining 
with MMP-19 antibody.
Discussion
In the present study attention was focused on the evaluation of 
the expression of the MMP-15 and MMP-19, the less investigated 
members of the family of metalloproteases, during the neoplastic 
progression in human intestinal mucosa. Our immunofluores-
cence analysis showed that MMP-15 is expressed in normal 
mucosa, although at low levels, whereas it increases in micro-
adenomas; such expression slightly decreased in carcinomas. 
These results were confirmed by western blotting and qRT-PCR 
data, with slight differences due to the various techniques used.
MMP-15 is a recently discovered membrane-type MMP (4); 
among the six membrane-type MMPs, only MMP-14 has been 
widely investigated and it is thought to play a crucial role in 
cellular invasion and proliferation (25). Thus, although MMP-15 
is supposed to play a similar role as MMP-14 in cell inva-
sion (9), less attention has been paid to MMP-15 and its role 
remains to be elucidated. The leading current hypothesis is that 
MMP-15 is involved in cancer progression, as inferable from 
the reports on the association of MMP-15 with various type of 
cancer (11-13). Furthermore, MMP-15 protein has been inves-
tigated and proposed as a possible prognostic factor in human 
colorectal carcinoma (15). Interestingly, our results indicate that 
the MMP-15 protein is highly expressed in the early stages of 
colorectal carcinogenesis. Indeed, it is now becoming evident 
that specific MMPs play a distinct roles in the early stages of 
colorectal tumorigenesis. Most of the evidence on this topic 
has accumulated for MMP-7 that could be considered as an 
oncogene; in fact, colorectal tumorigenesis is suppressed in 
mice lacking MMP-7 (26) and such MMP was showed to be 
involved in the initial steps of tumor development (27). Abraham 
et al (14) validated the anti-apoptotic activity of MMP-15 
and hypothesized that this protease connects metastasis and 
apoptosis resistance by an unknown regulatory mechanism. 
Furthermore, they suggested that cancer characteristics such 
as metastatic potential, which are thought as late events in 
cancer progression, could be present early by the selection for 
an anti-apoptotic phenotype. This hypothesis is in line with 
the data of our previous work (23), where we demonstrated that 
apoptosis decreases significantly in microadenomas compared 
to normal colonic mucosa; the fact that apoptosis decreases is 
crucial in the early stages of neoplastic transformation, while 
apoptosis decrement, not drastic as in previous stages, may be 
less relevant for cancer progression.
In this study we also analyzed for the first time the behavior 
of the MMP-19 protein during the major milestones of the 
transformation from normal mucosa to colorectal carcinoma. 
We reported that MMP-19 is expressed in normal mucosa at low 
levels and it is up-regulated during neoplastic progression. The 
increased expression of MMP-19 observed during the transition 
from microadenomas to cancer is confirmed by both the semi-
quantitative analysis of fluorescence, and western blotting profile 
as well as the data obtained by the qRT-PCR method. These 
findings strongly suggest that MMP-19 may play a role during 
malignant transformation. However, some other works reported 
conflicting data about the role played by MMP-19 in cancer: 
for example, MMP-19 is up-regulated in astroglial tumor and 
melanoma (17,18), and it is down-regulated or even lost during 
neoplastic progression in breast and skin (20,21).
Our observations consistently showed that the MMP-19 
protein is expressed only in the stromal compartment of the 
normal mucosa and its presence reaches the maximum levels 
in the tumor samples; all our qualitative and quantitative data 
(immunofluorescence, western blotting and qRT-PCR on 
mRNA) are consistent with this finding. On this consistent basis, 
the authors underlined the importance of MMP-19 mostly in the 
stromal ambit during tumorigenesis, although Bister et al (22) 
showed that MMP-19 is downregulated in the epithelium of inva-
sive colon cancer islands failing, indeed, in showing quantitative 
data.
Another topic of the present study was the identification of the 
types of stromal cells producing MMP-15 and -19 proteins. Both 
matrix metalloproteinases (15 and 19) were expressed by stromal 
fibroblasts in high percentage and by macrophages in smaller 
amounts, which is in accordance with previous data on cell types 
expressing MMP-19 (28,29). Several studies using mouse models 
of genetically altered fibroblasts demonstrated a direct involve-
ment of resident fibroblasts in the onset of cancer (30); moreover, 
both genetic and cell-biology studies indicate that tumor growth 
is not just determined by malignant cancer cells themselves, but 
also by the tumor stroma (31). There is also compelling evidence 
of the importance of the relationship between stromal cells and 
colorectal carcinoma cells in promoting MMP production either 
in tumor cells or in stromal cells (32,33). Some authors suggested 
the existence of a mechanism whereby invasive tumor cells 
secrete soluble factors which induce stromal cells (most prob-
ably fibroblasts) to produce MMPs (34), although several factors 
indicate that distinct mechanisms have evolved for the control of 
individual MMPs during tumor-host interaction.
In conclusion, in this study, for the first time, different behav-
iors of MMP-15 and -19 in human colorectal cancer development 
have been outlined; MMP-15 appears to be mainly active in the 
early stages of carcinogenesis performing a putative anti-apop-
totic role, MMP-19 seems to be involved in tumor progression, 
as its expression increases significantly during neoplastic trans-
formation.
The conventional view of MMPs as matrix-degrading 
enzymes, giving to these proteins a central role in tumor inva-
sion simply as a consequence of their activity, is now being 
challenged by new concepts of the roles of MMPs in tumor 
biology. Two are the key emerging concepts for the MMPs as 
a multifunctional group of molecules with complex biological 
actions: firstly, individual MMPs have a different role in the 
early stages of tumor development; secondly, the identification 
of an expanding range of MMP substrates which are non-matrix 
proteins, provides the basis for considering the burgeoning 
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range of biological functions attributed to MMPs, in particular 
those functions such as cell proliferation and cell death, crucial 
for tumor development and progression. The improved under-
standing of the biological roles of all the members of MMP 
family in colorectal cancer development should lead to a 
re-evaluation of the use of MMP inhibitors and highlights the 
importance of studying the MMPs in an integrated translational 
manner.
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